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Abstract
Background: Intrauterine growth restriction (IUGR), which refers to reduced fetal growth in the context of placental
insufficiency, is etiologically heterogeneous. IUGR is associated not only with perinatal morbidity and mortality
but also with adult-onset disorders, such as cardiovascular disease and diabetes, posing a major health burden.
Placental epigenetic dysregulation has been proposed as one mechanism that causes IUGR; however, the spectrum of
epigenetic pathophysiological mechanisms leading to IUGR remains to be elucidated. Monozygotic monochorionic
twins are particularly affected by IUGR, in the setting of severe discordant growth. Because monozygotic twins have
the same genotype at conception and a shared maternal environment, they provide an ideal model system for
studying epigenetic dysregulation of the placenta.
Results: We compared genome-wide placental DNA methylation patterns of severely growth-discordant twins to identify
novel candidate genes for IUGR. Snap-frozen placental samples for eight severely growth-discordant monozygotic
monochorionic twin pairs were obtained at delivery from each twin. A high-resolution DNA methylation array
platform was used to identify methylation differences between IUGR and normal twins. Our analysis revealed
differentially methylated regions in the promoters of eight genes: DECR1, ZNF300, DNAJA4, CCL28, LEPR, HSPA1A/L,
GSTO1, and GNE. The largest methylation differences between the two groups were in the promoters of DECR1
and ZNF300. The significance of these group differences was independently validated by bisulfite pyrosequencing,
implicating aberrations in fatty acid beta oxidation and transcriptional regulation, respectively. Further analysis of the
array data identified methylation changes most prominently affecting the Wnt and cadherin pathways in the
IUGR cohort.
Conclusions: Our results suggest that IUGR in monozygotic twins is associated with impairments in lipid metabolism
and transcriptional regulation as well as cadherin and Wnt signaling. We show that monozygotic monochorionic
twins discordant for growth provide a useful model to study one type of the epigenetic placental dysregulation
that drives IUGR.
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Background
Fetal growth restriction is considered a disorder with sig-
nificant etiologic heterogeneity, as there are many known
fetal and maternal causes of growth restriction [1]. When
growth restriction occurs in the context of placental insuffi-
ciency, it is termed intrauterine growth restriction (IUGR).
IUGR, which affects 10–15 % of pregnancies [2], is associ-
ated not only with significant perinatal morbidity and
mortality [2] but also with adult-onset diseases, such as car-
diovascular disease and diabetes [3–5]. Thus, IUGR poses a
major human health burden. The association between
IUGR and adult-onset disease is thought to result
from fetal programming, wherein fetal adaptive mech-
anisms “set” metabolic regulatory pathways in re-
sponse to fetal environments, such as limited
nutrition. Consequently, in a society where postnatal
nutrient supply exceeds the prenatally “sensed” de-
mands, these metabolic set points predispose the or-
ganism to disease later in life [3–5]. The molecular
basis of fetal programming is likely to be mediated by
epigenetic mechanisms such as DNA methylation.
Early embryonic development depends on normally func-
tioning epigenetic modifications such as DNA methylation,
to guide spatial and temporal gene activation and repres-
sion that mediate normal growth, cell differentiation and
morphogenesis [6]. Likewise, normal placental growth re-
quires appropriate epigenetic regulation of gene expression.
The spectrum of epigenetic pathophysiological mecha-
nisms leading to IUGR remains to be elucidated. These
epigenetic alterations, which can involve the fetus and/or
the placenta, may affect expression of imprinted or non-
imprinted genes important for normal fetal growth and
development. Imprinted genes are normally expressed from
a single allele in a parent of origin-specific manner [6].
This expression pattern is coordinated via CpG-rich
differentially methylated regions (DMRs) in imprinted
domains. Loss of imprinting, characterized by aberrant
methylation of an imprinted DMR, may restrict the growth
of both the placenta and the fetus, causing IUGR, as in
the undergrowth disorder Russell-Silver syndrome (OMIM
180860) [6].
IUGR due to placental insufficiency typically exhibits
specific diagnostic vascular and pathological placental fea-
tures. It has been proposed that the intrauterine environ-
ment can affect placental development and alter placental
gene expression, thereby reducing the placenta’s ability to
support optimal fetal growth. Studies investigating placen-
tal epigenetic dysregulation have identified altered DNA
methylation of genes involved in placental development,
including trophoblast differentiation, angiogenesis, and
endocrine signaling [7]. Placental epigenetic dysregula-
tion, in particular altered DNA methylation, has been
proposed as a mechanism underlying the aberrant gene
expression in the pathophysiology of IUGR [7].
Monochorionic (MC) twins are monozygotic (MZ; i.e.,
identical) twins that share the same placenta. They pro-
vide an ideal model for studying epigenetic regulation of
the placenta because of their identical genotypes and
shared maternal environment. Monochorionic twins are
also particularly affected by IUGR in the setting of se-
vere discordant growth, which occurs in 20 % of MC
pregnancies [8, 9]. Severe discordant growth is a major
contributor to perinatal morbidity and mortality in MC
twin pregnancies. Growth discordance is 2.5-fold higher
in MC versus dichorionic twin pregnancies [10]. IUGR
in the setting of severe growth discordance of MC twins
is typically characterized by unequal placental share, where
the smaller twin has a smaller share of the placenta [11]. A
better understanding of the placental dysfunction under-
lying MC growth discordance not only holds promise for
improving postnatal outcomes in this population but will
also offer clues to understanding IUGR on a wider scale in
singletons and the molecular basis of fetal programming
relevant to increased risks for adult-onset disease.
In this study, we compared genome-wide placental
DNA methylation (DNAm) patterns of severely growth-
discordant MC twins. Our microarray analysis identified
novel candidate differentially methylated regions for
IUGR, including those overlapping the promoters of three
genes DECR1, LEPR, and ZNF300. These differences were
statistically significant when validated by an independent
methodology, bisulfite pyrosequencing. A pathway ana-
lysis supported a role for epigenetic dysregulation in IUGR
pathogenesis of the Wnt and cadherin pathways, which
are known to be important in embryonic development.
While a single prior study reported targeted gene expres-
sion in growth-discordant MC twins [12], the current
study is the first genome-wide investigation of DNAm in
MC growth-discordant twins.
Results
We sought to identify novel candidate genes for IUGR
by comparing genome-wide placental DNAm using Illu-
mina HumanMethylation450 arrays of eight severely
growth-discordant MC twin pairs. The clinical charac-
teristics of the MZ twins in this study are detailed in
Additional file 1: Table S1. Growth-discordant twin pairs
had birth weight differences between 21 and 59 %. All
growth-restricted twins measured below the tenth cen-
tile in weight for gestational age, while their normal
weight counterparts measured above the tenth centile.
A description of placental pathology for these twins is
found in Additional file 1: Table S2. Pathological features
typically associated with IUGR, such as velamentous
cord insertion, advanced villous maturity, thrombosis,
and infarction, were consistently present in the IUGR-
affected twin’s placental share.
Roifman et al. Clinical Epigenetics  (2016) 8:70 Page 2 of 13
Genome-wide DNA methylation patterns
Differential DNAm analysis was performed on a total of
399,118 sites after quality control analysis of the data
(see the “Methods” section). When comparing global
DNAm patterns using unsupervised hierarchical cluster-
ing, twins were most similar to their own co-twins in 7/
8 discordant twin pairs (Fig. 1). This suggests that IUGR
is not associated with genome-wide DNAm changes, a
finding previously described in other epigenome-wide
association studies [13, 14].
Differentially methylated regions associated with IUGR
To find genomic regions with DNAm differences in IUGR,
we used bump hunting [15], which is known to improve
the statistical power and robustness by combining methyla-
tion patterns across nearby CpG sites in smaller datasets
[16]. After accounting for the potential confounding effects
of the twins’ sex, gestational age, and maternal age (see the
“Methods” section), our analysis revealed eight statistically
significant (p < 0.05) DMRs where the magnitude of the
DNAm differences between IUGR and the other twin
exceeded 10 % (Table 1). These DMRs match the pro-
moters of eight genes (listed in decreasing order of methy-
lation difference between IUGR and controls): DECR1,
ZNF300, DNAJA4, CCL28, LEPR, HSPA1A/L, GSTO1,
GNE (Table 1). For six of eight genes, the IUGR twin dem-
onstrated a gain of DNAm. Inspection of individual DMRs
revealed consistent patterns of DNAm change that also
corresponded well with other epigenetic features, such as
histone marks, DNase hypersensitivity regions, and tran-
scription factor binding sites (Figs. 2, 3, 4; Additional file 1:
Figures S1–S2).
DECR1, ZNF300, and LEPR DNA methylation results
Three of the eight genes identified in the bump hunting
analysis were chosen for validation by targeted bisulfite py-
rosequencing (PyroMark Q24; Qiagen) (see the “Methods”
section). DECR1 and ZNF300 were selected because they
exhibited the largest methylation differences in our analysis,
and LEPR was chosen because of its recent association with
IUGR in a separate MZ-MC twin study [12].
The largest methylation differences were found in the
promoter region of the DECR1 gene, which encodes 2,4
dienoyl-CoA reductase (DECR), a mitochondrial enzyme
in the unsaturated fatty acid beta oxidation pathway vital
for unsaturated fat metabolism.
Placental samples from the IUGR twins exhibited a gain
of methylation in all of the CpG sites within the CpG is-
land located in the DECR1 promoter region, compared to
their normal weight counterparts (Fig. 2) (Table 1). The
mean DNAm differences in IUGR (also known as delta
beta or Δβ) across all twin pairs for the DECR1 was 17.5 %
(bump hunting p = 0.0027), reaching as high as 22.5 and
21.4 %, respectively, for the top two differentially methyl-
ated CpG sites within the DMR. There was a very substan-
tial gain in DNAm levels in five of eight discordant twin
pairs, ranging on average between 14 and 42 % across
the DMR, and a small gain in one other pair (4 %). The
remaining two twin pairs showed no difference in
DNAm (less than 1 % change); see Additional file 1:
Figure S3 for details.
The results obtained for the two top DECR1-promoter
CpGs, cg01971612 and cg18485485, were independently
validated through bisulfite pyrosequencing analysis in the
same set of twins (Fig. 5a). A significant difference in
DNAm (mean Δβ gain of 12.6 %) was observed in the
IUGR compared to the normal twin group for both CpG
sites (paired t test, two-tailed, p = 0.021) (Additional file 1:
Figure S4, see the “Methods” section).
Following DECR1, the next largest DMR showing
16 % gain of methylation in IUGR (p = 0.0032) was lo-
cated in the promoter of the zinc finger protein-coding
gene, ZNF300, (Fig. 3), which plays an important role
in tumor growth and immune modulation. Five of the
twin pairs showed a methylation gain between 18 and
32 % in IUGR at this DMR, with two more pairs showing
small or negligible gains (5.4 and 1.3 %, respectively). The
remaining one pair showed a small DNAm loss of 4.3 %;
see Additional file 1: Figure S5 for details.
Fig. 1 Genome-wide unsupervised hierarchical clustering. Correlation between global DNA methylation patterns involving 399,118 autosomal
CpGs was highest between co-twins for 7/8 discordant twin pairs, with the twin pair 5063D being the only exception. This suggests that IUGR is
not associated with genome-wide DNA methylation changes. Monozygosity was molecularly confirmed for all twin pairs. Pearson correlation with
average linkage was used as the clustering metric, with the scale shown on the right. Samples 4273D, 5264D, 5063D, and 5321D overlap with
samples from a previous study [12]
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Table 1 Differentially methylated regions (DMR). Shown are the DMRs with the significance level p < 0.05 as reported by the
bumphunter software and spanning at least three CpGs with the average DNA methylation differences (delta beta) between IUGR
and healthy twins above 10 % by magnitude in all CpGs. The DMRs are sorted by the magnitude of delta-beta differences. DMR
length is measured in basepairs. Gene matches represent the overlaps between the DMR and the gene’s body or promoter region
up to 1500 bp from the transcription start site. Genome coordinates are given with respect to hg19 genome assembly
Chr Start End Δβ p value CpGs Length Gene
8 91013426 91013697 0.175 0.0027 6 272 DECR1
5 150284416 150284796 0.161 0.0032 7 381 ZNF300
15 78556834 78556945 −0.152 0.0082 5 112 DNAJA4
5 43396953 43397288 −0.139 0.0081 6 336 CCL28
1 65991176 65991664 0.133 0.0329 3 489 LEPR
6 31783322 31783482 0.130 0.0069 7 161 HSPA1A/L
10 106014615 106014893 0.126 0.0401 3 279 GSTO1
9 36258114 36258885 0.120 0.0114 6 772 GNE
Fig. 2 DNAm changes in IUGR twins in DECR1 promoter. Methylation levels in IUGR twins (orange circles) and unaffected co-twins (blue crosses)
are shown, arranged vertically for each CpG in the region spanning the DECR1 gene promoter. The mean methylation levels are shown for the
IUGR cohort (red line) and controls (blue line). The top six CpGs with methylation change above 10 %, and no more than 500 bp apart, comprise
the DMR (red box), which also corresponds to the wider gap between the red and blue lines. Other genomic features, such as CpG islands, histone
marks, DNase hypersensitivity clusters, and transcription factor binding sites are also shown. Visualization is provided by the UCSC Genome
Browser and was inspired by DMRcate software [66]
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The results for three CpG sites (cg04675542, cg02343823,
cg08580836) within the ZNF300 DMR were independ-
ently validated using targeted bisulfite pyrosequencing
analysis (Fig. 5b). Significant differences were demon-
strated for the three CpG sites in IUGR compared to the
normal twin group (mean Δβ gain of 13.7 %; paired t test,
two-tailed, p = 0.016) (Additional file 1: Figure S6).
In the LEPR gene, placental samples from the IUGR
twins exhibited a gain of methylation at all CpG sites lo-
cated near the promoter region (Fig. 4). The DMR showed
an average DNAm gain of 13.3 % (p = 0.033) in IUGR
twins compared to their healthy counterparts, with four of
eight discordant twin pairs having very substantial gain of
between 13 and 33 %. A small gain was found in three
other pairs (between 3.4 and 6.4 %); the remaining one
pair showed negligible DNAm difference (1.7 % change);
see Additional file 1: Figure S7 for details.
DNAm levels for the top CpG site (cg08234308)
within the LEPR DMR were independently validated
using targeted bisulfite pyrosequencing analysis (Fig. 5c)
and demonstrated a significant difference (mean Δβ gain
of 11.2 %; paired t test, two-tailed, p = 0.022) between the
IUGR and the normal twin groups (Additional file 1:
Figure S8).
Differentially methylated CpG sites associated with IUGR
To assess the broader functional implications of the
genome-wide DNAm changes in IUGR, our analysis was
extended to the level of individual CpGs (see the “Methods”
section). This analysis identified 296 statistically signifi-
cant CpG sites (Fig. 6), which overlap 172 genes or
gene-promoter regions (Additional file 2: Table S3). As
an additional validation step, using these 296 CpGs to
quantify the methylation profiles resulted in the IUGR
cohort clustering separately from the group of eight un-
affected twins (Fig. 7). This suggested that the identified
collection of CpGs which overlap the list of eight gen-
omic regions identified by bump hunting is also
Fig. 3 DNAm changes in IUGR twins in ZNF300 promoter. Methylation levels in IUGR twins (orange circles) and unaffected co-twins (blue crosses)
are shown, arranged vertically for each CpG in the region spanning the promoter of the ZNF300 gene transcript. The mean methylation levels are
shown for the IUGR cohort (red line) and controls (blue line). The top seven CpGs with methylation change above 10 % comprise the DMR (red
box), which also corresponds to the wider gap between the red and blue lines
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Fig. 4 DNAm changes in IUGR twins in LEPR promoter. Methylation levels in IUGR twins (orange circles) and unaffected co-twins (blue crosses) are
shown, arranged vertically for each CpG in the region spanning the promoter of one of the LEPR gene transcripts. The mean methylation levels
are shown for the IUGR cohort (red line) and controls (blue line). The top three CpGs with methylation change above 10 % comprise the DMR
(red box), which also corresponds to the wider gap between the red and blue lines
Fig. 5 Validation of candidate IUGR regions by bisulfite pyrosequencing. Bar charts representing the DNA methylation levels at two CpG sites
overlapping DECR1 (cg01971612, cg18485485) (a), three CpG sites overlapping ZNF300 (cg04675542, cg02343823, cg08580836) (b), and one CpG
site overlapping LEPR (cg08234308) (c) in both IUGR (gray color) and healthy co-twins (black color)
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sufficiently representative of methylation differences in
IUGR, and is therefore also likely to reflect broad func-
tional patterns related to the disorder.
Functional enrichment
Enrichment analysis showed a significant over-representation
of functional groups highly relevant to the IUGR pheno-
type, such as fetal development, intracellular signaling, and
cell adhesion. For example, 55 of the 172 genes were in-
volved in “anatomical structure development” (p = 1.0e−7
after false discovery rate (FDR) correction) and 40 genes
were associated with “nervous system development” (cor-
rected p = 2.6e−10). As many as 70 genes, or 41 % of our
list, were annotated as “intrinsic to membrane” (corrected
p = 0.011). Other enriched functional groups were related
to cell adhesion, developmental processes, and regulation
of transcription (Additional file 2: Table S4). We also ana-
lyzed the enrichment of the 296 individual CpG sites in
the context of much wider genomic regions, extending up
to 100,000 bp to the nearest gene, which facilitated the
functional assignment of intergenic CpGs. The functional
categories detected in this analysis were related to develop-
mental processes, lipid metabolism (e.g., lipopolysacchar-
ide metabolic process, response to cholesterol) and cellular
response to various stimuli (Additional file 2: Table S5).
The enriched functional groups such as “intrinsic to
membrane,” “anatomical structure development” and
“nervous system development” also included most of
the genes from the Wnt and cadherin pathways. Ana-
lysis of pathway enrichment confirmed that the cad-
herin pathway, which mediates calcium-ion-dependent
cell adhesion, was prominent among the candidate genes
(20 genes, p = 5.9e−10 after FDR correction), as was the
related Wnt signaling pathway (23 affected genes, p = 5.0e
−8 after FDR correction).
Discussion
To our knowledge, this is the first report of genome-
wide DNA methylation analysis in growth-discordant
MC twins. None of the top eight genes identified in our
analysis is associated with a known imprinted region,
implicating a mechanism of IUGR that is distinct from
those impacted in imprinting disorders. Two of the
eight genes differentially methylated in the IUGR group
(DECR1 and GSTO1) have been previously associated
with IUGR (in animals and singleton humans, respect-
ively), suggesting (at least in part) a common patho-
genic mechanism for IUGR in singletons versus that in
MC growth-discordant twins [17, 18].
In general, for each DMR, the patterns of DNAm dif-
ferences in IUGR (Δβ) were consistent across the major-
ity of twin pairs, although the magnitude of Δβ across
different twin pairs varied (Additional file 1: Figure S9).
Overall, this heterogeneity across the twin pairs is not
unusual for either MZ twin studies [14] or for IUGR
studies [19].
The IUGR twins in our series exhibited heterogeneity of
IUGR placental pathology (Additional file 1: Table S2),
which has been shown in other larger scale studies as well
[12] and may relate to both cause and/or effect of the het-
erogeneity in the results of our epigenetic analysis.
Prominent biological networks in IUGR
Our study demonstrates an association of IUGR with
DNA methylation changes that impact the regulation of
genes relating to lipid metabolism and to nervous system
development. Interestingly, neonates with IUGR exhibit
reduced lipid stores with significant neonatal metabolic
morbidity [20] and are known to suffer neurodevelopmen-
tal difficulties compared to age-matched controls [21].
Our results implicate a role for altered DNA methylation
Fig. 6 CpG sites used for functional enrichment analysis. Only the CpGs that have a DNAm difference at least 10 % in IUGR twins were considered.
A set of 296 CpGs (numbers in red) was selected as the sites that were identified by limma regression analysis after accounting for confounding effects
and also passed at least one of the non-parametric tests for IUGR association. The right Venn diagram shows the number of genes matching each
criteria of significance, where 172 genes comprise the set tested for functional enrichment
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in the cause and/or effect of these two major IUGR-
related clinical impairments.
The largest methylation differences were found in the
promoter region of the DECR1 gene. This gene encodes
DECR, the rate-limiting mitochondrial enzyme in un-
saturated fatty acid beta oxidation, which is required
for growth and neurodevelopment [22] and has also
been implicated in adaptive cellular stress-response
mechanisms in IUGR animals [17]. An association be-
tween unsaturated fatty acids and intrauterine growth
has been previously reported in that prenatal supple-
mentation of the unsaturated fatty acid, omega-3, has
been shown to increase birth weight [23], while impaired
beta oxidation in fetuses with IUGR has also been sug-
gested by several other studies [17, 24, 25]. Biochem-
ically diagnosed DECR deficiency has been reported in
two unrelated individuals, who had poor growth,
hypotonia, developmental delay, and severe encephal-
opathy; one of these individuals died in infancy [26, 27].
Studies of Decr1−/− mice suggest that the enzyme is re-
sponsible for the induction of gluconeogenesis during
fasting [28].
The next largest methylation difference identified in
our analysis was a gain of methylation in the promoter
of the ZNF300 gene in the IUGR group compared to
controls. ZNF300 encodes a zinc finger protein, which
functions as a ubiquitous transcriptional repressor [29].
Hypermethylation of this gene has been associated with
decreased gene expression, modulation of inflammatory
pathways, and tumor development [30]. ZNF300 knock-
down studies revealed this gene’s role in cell differenti-
ation [31]. Although ZNF300 has not previously been
associated with IUGR, its strong role in cancer develop-
ment supports its potential to impact fetal growth.
Another highly ranked candidate gene is the LEPR gene,
which encodes the leptin receptor. LEPR deficiency in
humans leads to morbid obesity and pituitary dysfunction
[32–34], and polymorphisms in the LEPR gene have been
associated with birth weight [35], obesity [36], and type II
diabetes [37]. In animal studies, maternal diet restriction
has been associated with subsequent obesity at a few
months of age as well as reduced birth weight of the off-
spring and reduced expression of LEPR [38]. Lepr-defi-
cient (Lepr db/db) mouse models are often used for
studying type II diabetes (reviewed in [39]). To date, our
study is the first to link increased LEPR methylation with
IUGR in humans.
One previous study of growth-discordant MZ-MC twins
assessed placental expression of 88 angiogenesis-related
genes, the leptin (LEP) and LEPR genes, and also assessed
methylation using an assay targeting 64 CpGs overlapping
the LEP promoter [12]. They found that the smaller twins
exhibited a significant increase in LEP expression along
with an average gain of methylation of the LEP promoter
region [12]. Four twin pairs used in that study were
also used in our study (see the “Methods” section and
Additional file 1: Tables S1–S2). It was difficult to com-
pare Schrey et al.’s [12] data to our data as only six of the
63 CpG sites tested in the LEP promoter region are cov-
ered by the Illumina 450k array. Our analyses of the six
CpGs for the eight MZ twin pairs and the four twin pairs
overlapping the two studies did not show any significant
gain of methylation in the LEP promoter region. That is,
we suggest that the significant differences in LEP methyla-
tion found by Schrey and colleagues [12] were driven by
CpGs not assessed in our study. The Schrey study also re-
ported a decrease in LEPR expression in the IUGR group,
though this difference was not significant [12]. A decrease
in LEPR expression would be consistent with the gain of
LEPR methylation found in the current study. In general,
however, differences in the results of our study and those
Fig. 7 The putatively affected CpGs are able to separate the IUGR
cohort from the normal cohort. Clustering heatmap shows IUGR
(magenta) and normal (green) twin samples, shown in columns,
forming two separate clusters in Manhattan distance metric. Rows
represent the 296 affected CpGs. The color scale at the top indicates
the range of the DNAm values
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found by Schrey and colleagues [12] may largely be attrib-
uted to the use of different methodologies: genome-wide
DNA methylation with limited coverage at individual pro-
moter regions in this study, and gene expression analysis
by Schrey and colleagues.
The remainder of the genes with methylation differences
identified in the IUGR group (DNAJA4, CCL28, HSPA1A/
L, GSTO1, and GNE) function in growth, immunity, and
cell metabolism. The GSTO1 gene, which encodes an
arsenic detoxification enzyme, glutathione S-transferase
omega 1, is the only gene in this list to have a prior associ-
ation with fetal growth restriction [18]. This enzyme also
plays a role in the inflammatory response, apoptosis, and
tumor development (reviewed in [40]). The mouse Gsto1
knockout model shows impaired detoxification of arsenic,
a known human carcinogen [41]. DNAJA4 and HSPA1A/L
encode heat-shock proteins. A variety of tumors exhibit
hypermethylation of DNAJA4, which has been associ-
ated with gene silencing [42, 43]. Increased expression
of DNAJA4 has been shown to suppress tumor invasion
[42–44]. CCL28, which encodes the growth factor che-
mokine ligand 28 [45], increases placental cell apoptosis
[46] and is downregulated in a variety of human malig-
nancies [47, 48]. GNE encodes a key enzyme in sialic
acid biosynthesis, a process that is often upregulated in
tumor development [49]. Reduced sialylation has been
shown in heterozygous Gne-deficient mice, while complete
knockouts are embryonically lethal [50]. Gne-deficient
mouse embryonic stem cells exhibit impaired proliferation
and cell differentiation, particularly affecting muscle [51].
In humans, GNE deficiency causes Nonaka myopathy [52].
Collectively, the aberrant methylation of the genes found
in our IUGR cohort appears to drive increased apoptosis,
impaired cellular metabolism as well as poor growth, and
invasion of the placenta.
Prominent cellular pathways in IUGR
The Wnt and cadherin pathways were significantly over-
represented in the list of candidate genes generated from
296 individual CpGs representative of the IUGR epige-
nome. Wnt signaling is well known for its role in carcino-
genesis and embryonic development, specifically body axis
patterning, cell proliferation, cell migration and cell differ-
entiation [53, 54]. Wnt signaling plays a role in placental
development (trophoblast proliferation and invasion) and
is altered in gestational diseases (reviewed in [55]). Our
group has previously shown that the promoter region of
the WNT2 gene is differentially methylated in the placen-
tas of IUGR singletons versus controls [19]. WNT2 gene
expression has also been proposed to mediate poor mater-
nal nutrition and fetal growth restriction [56]. Our results
suggest that upregulation of DNAJA4 may be an important
downstream effect of impaired Wnt signaling in IUGR.
Cadherins are a group of “calcium-dependent adhesion”
transmembrane proteins that facilitate normal embryonic
tissue organization and trophoblast invasion via cell-to-cell
adhesion and cell migration (reviewed in [57]).
The precise mechanisms by which Wnt and cadherin
signaling play a role in IUGR is unknown. To the best of
our knowledge, this is the first report that prominently
highlights these pathways in the pathogenesis of IUGR
in growth-discordant MC twins.
Conclusions
This is the first report of a genome-wide DNA methyla-
tion analysis using the Infinium HumanMethylation450
BeadChip platform to investigate IUGR in MC growth-
discordant twins. We identified eight candidate genes that
are epigenetically altered in IUGR. Our results suggest that
dysregulation of lipid metabolism and transcription, as well
as impaired cadherin and Wnt signaling, are associated
with IUGR. Collectively, the genes exhibiting differential
regulation in growth-restricted fetuses may underlie fetal
programming and may generate candidate biomarkers for
IUGR and/or its related adult-onset diseases. These results
should be validated by further investigation of DNA
methylation and/or gene expression of the identified candi-
date genes in a large cohort of MZ-MC growth-discordant
twins. Finally, we propose the growth-discordant MC twin
model as a useful tool in the genome-wide study of IUGR.
Methods
Sample selection
This study was approved by the Mount Sinai Hospital
(MSH) and the Hospital for Sick Children (SickKids)
Research Ethics Boards (REB # 10-0128-E). Participants
were recruited from the MSH high-risk obstetrical clinic,
following diagnosis of MC discordant growth and pla-
cental insufficiency. Informed consent was obtained
from each participant. Growth discordance was defined
as a birth weight difference >20 % between the co-twins
[58]. Birth weight was plotted as percentile for gesta-
tional age using a Canadian population-based reference
chart [59]. Placental insufficiency was defined as intermit-
tent absent or reversed end-diastolic flow. A full list of the
inclusion and exclusion criteria is found in Additional file 1:
Table S6.
Following these criteria, we recruited eight MC growth-
discordant twin pregnancies.
Placental characteristics are detailed in Additional file 1:
Table S2. Four of these pairs overlap with a previous
MZ twin study of IUGR that evaluated expression of
angiogenesis-related genes and targeted DNA methyla-
tion of one gene [12].
Placental sampling was performed immediately after de-
livery by members of the Research Center for Women’s
and Infants’ Health BioBank, Toronto. At delivery, cord
clamps were labeled as twin “A” or “B” to distinguish each
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twin’s placental share. Snap-frozen placental samples were
obtained from each twin according to a previously stan-
dardized protocol (http://biobank.lunenfeld.ca/). The re-
mainder of each placenta was sent for pathological
examination. Monozygosity was molecularly confirmed
for all twin pairs.
Genome-wide DNA methylation analysis
Genomic DNA from the placental samples was bisulfite
treated (Qiagen). DNA methylation was then analyzed
using the Infinium HumanMethylation450 BeadChip
array (Illumina, San Diego, CA, USA) following the
standard Infinium HD Assay Methylation Protocol
Guide (Part #15019519, Illumina). The array assesses
DNA methylation at single CpG sites genome-wide; how-
ever, it does not differentiate between 5-methylcytosine
and 5-hydroxymethylcytosine, which is a recognized limi-
tation of this platform [60].
All samples were run on the array together within the
same batch and passed quality control. Data pre-processing
such as background subtraction and normalization to in-
ternal array controls was performed in Illumina GenomeS-
tudio v2011.1 Methylation Module 1.9 software (http://
www.illumina.com).
CpG probe filtering
The 485,577 methylation probes from the Human-
Methylation450 array were filtered by removing probes
with missing DNA methylation values (beta values either
missing or exactly zero) and with detection p values
above the significance threshold 0.05. We also removed all
cross-reactive probes annotated as such in [61]. To
minimize possible confounding effect by ethnicity or sex,
especially in the context of unpaired statistical tests be-
tween IUGR and control groups (Fig. 6), all probes for
which there was a known SNP of at least 1 % minor allele
frequency within 5 bp of the targeted cytosine (based on
the annotation in [61]) as well as probes located on sex
chromosomes were excluded, leaving 399,118 autosomal
CpG sites available for analysis.
Detection of differentially methylated regions
To detect the differentially methylated regions, we used
the bump hunting method of Jaffe and colleagues [15] im-
plemented in the bumphunter Bioconductor package, set-
ting the cutoff threshold of 10 % for the Δβ methylation
difference in IUGR. To account for confounding effects,
the model design matrix consisted of an intercept term,
IUGR indicator variable, and twin sex, maternal age and
twin’s gestational age as additional confounders. Statistical
significance of the detected bumps was assessed in com-
parison to B = 1000 randomized bootstrap iterations.
From the resulting collection of bumps, we retained only
the DMRs that contained at least three CpGs with gaps
no more than 500 bp, and exhibited methylation differ-
ences of 10 % or higher in IUGR while satisfying the sig-
nificance level p < 0.05.
Selection of CpG sites for functional enrichment analysis
For the analysis of methylome-wide functional enrich-
ment in IUGR, we included not only the eight DMRs
from the bump hunting analysis, but also the CpG sites
that were significantly different in IUGR compared to
healthy co-twins. These individual CpG sites were iden-
tified using a combination of statistical criteria to ac-
count for the small sample size.
Three sets of statistical tests were performed on eight
growth-discordant twin pairs at each CpG site. First, we
used limma regression modeling, which is particularly
well suited for small sample sizes thanks to its method-
ology of information borrowing across CpG sites. The
model was applied to DNAm data log-transformed into
M-values to improve statistical accuracy [62]. The twin’s
sex, gestational age and maternal age were included in
the model as covariates. CpGs were considered signifi-
cant if the limma regression p values corresponding to
the IUGR status satisfied the significance level p < 0.05.
Second, we used a non-parametric approach to test
the between-group differences, comparing the placental
methylation levels in the group of eight healthy individ-
uals (controls) and the group of eight affected IUGR in-
dividuals. The unpaired Mann–Whitney U test was used
for each CpG site.
Finally, the changes in DNA methylation level in healthy
twins versus their IUGR-affected counterparts were com-
pared using the paired Wilcoxon signed-rank test, which
attempted to identify a consistent pattern of DNAm shift
across all eight pairs, although not necessarily an overall
difference between the IUGR and the healthy cohorts.
Thus, the two non-parametric tests are complementary in
finding pattern of differences across the twin pairs.
Given the large number of probes tested and a rela-
tively small sample size, the standard methods of cor-
rection for multiple testing (such as Bonferroni or
Benjamini-Hochberg FDR procedures) were too re-
strictive to confirm the validity of any of the individual
tests. Therefore, we decided on a pragmatic strategy of
using the probe-level statistical tests as guidance and
complemented them with an effect-size threshold. We
considered the threshold of 10 % as sufficiently strin-
gent because relatively few CpG sites had a DNA
methylation change exceeding 10 % by magnitude.
For validation purposes, we used unsupervised clustering
to confirm that the resulting set of CpG sites contained a
sufficiently discernible biological signal unobscured by the
potential false positives or other stochastic noise in the se-
lected loci. All DNAm profiles were first reduced to the set
of probes with significant differences in IUGR according to
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our selection criteria. Thereafter, hierarchical clustering
was applied to discern the different groups in our cohort.
Functional enrichment analysis
To identify prominent clinical mechanisms affecting
and/or affected by growth restriction in our cohort, the
172 genes with evidence of differential methylation were
investigated with respect to their functions and major
biological roles. The analysis was performed using DA-
VID [63]. All p values were FDR corrected.
The 296 putatively affected CpG set was also analyzed
in the context of wider genomic regions using GREAT
[64]. We set the distal extension to the nearest genes as
100 kbp. The background set of probes to which the com-
parison was made was defined as the 399,118 autosomal
CpGs used as the initial input to our analysis pipeline.
Validation analysis of DNA methylation using bisulfite
pyrosequencing
Results of top candidate CpG sites (cg01971612 and
cg18485485 for DECR1; cg04675542, cg02343823, and
cg08580836 for ZNF300; and cg08234308 for LEPR)
were validated using pyrosequencing of bisulfite converted
DNA (PyroMark Q24; Qiagen). Polymerase chain reaction
(PCR) and sequencing primers were designed using Pyro-
Mark Assay Design 2.0. All procedures were performed
according to the manufacturer’s protocols [65]. The pres-
ence of 5-methylcytosine versus 5-hydroxymethylcytosine
could not be distinguished using this method.
Additional files
Additional file 1: Supplementary Figures and Tables. (PDF 1827 kb)
Additional file 2: Supplementary Tables S3–S5. (XLSX 86 kb)
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